$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

Objective : To quantify the economic value of the Sirolimus fluting Stent ($CYPHER^{TM}$) in treating acute coronary heart disease (CMD), and to assist in determining an adequate level of reimbursement for $CYPHER^{TM}$ in Korea. Methods : A decision-analytical model, developed by the Belgium Health Economics Disease Management group, was used to investigate the incremental cost-effectiveness of $CYPHER^{TM}$ versus conventional stenting. The time horizon was five years. The probabilities for clinical events at each node of the decision model were obtained from the results of large, randomized, controlled clinical trials. The initial care and follow-up direct medical costs were analyzed. The initial costs consisted of those for the initial procedure and hospitalization, The follow-vp costs included those for routine follow-up treatments, adverse reactions, revascularization and death. Defending on the perspective of the analysis, the costs were defined as insurance covered or total medical costs (=sum of insurance covered and uncovered medical costs). The cost data were obtained from the administrative data of 449 patients that received conventional stenting from five participating Korean hospitals during June 2002. Sensitivity analyses were peformed for discount rates of 3, 5 and 7%. Since the major clinical advantage of $CYPHER^{TM}$ over conventional stenting was the reduction in the revascularization rates, the economic value of $CYPHER^{TM}$, in relation to the direct medical costs of revascularization, were evaluated. If the incremental cost of $CYPHER^{TM}$ per revascularization avoided, compared to conventional stenting, was no higher than that of a revascularization itself, $CYPHER^{TM}$ would be considered as being cost-effective. Therefore, the maximum acceptable level for the reimbursement price of $CYPHER^{TM}$ making the incremental cost-effectiveness ratio equal to the cost of a revascularization was identified. Results : The average weighted initial insurance covered and total medical costs of conventional stenting were about 6,275,000 and 8,058,000 Won, respectively. The average weighted sum of the initial and 5-year follow-up insurance covered and total medical costs of conventional stenting were about 13,659,000 and 17,353,000 Won, respectively. The estimated maximum level of reimbursement price of $CYPHER^{TM}$ from the perspectives of the insurer and society were $4,126,897{\sim}4,325,161$ and $4,939,939{\sim}5,078,181$ Won, respectively. Conclusion : By evaluating the economic value of $CYPHER^{TM}$, as an alternative to conventional stenting, the results of this study are expected to provide a scientific basis for determining the acceptable level of reimbursement for $CYPHER^{TM}$.

참고문헌 (31)

  1. Detels R, Breslow L. Current scope and concerns in public health. In: Oxford textbook of public health. 4th ed. Oxford University Press; 2002 
  2. Glagov S, Weisenberg E, Zarins CK, Stankynavicius R, Kloettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. New England J Med 1987; 316: 1371-1375 
  3. National Heart, Lung, and Blood Institute. Morbidity and mortality: 1998 chartbook on cardiovascular, lung, and blood disease. National Institute of Health; 1998 
  4. 사망원인 통계연보. 통계청; 2001 
  5. Gil R, Di Mario C, Prati F, von Birgelen C, Ruygrok P, Roelandt JR, Serruys PW. Influence of plaque composition on mechanisms of percutaneous transluminal coronary balloon angioplasty assessedby ultrasound imaging. AHJ 1996; 131: 591-597 
  6. Di Sciascio G, Patti G, Nasso G, Manzoli A, D' Ambrosio A, Abbate A. Early and long-term results of stenting of diffuse coronary artery disease. Am J Cardiol 2000;86(11): 1166-1170 
  7. lijima R, Nakamura M, Kitagawa Y. Comparison of the efficacy of cutting balloon and balloon angioplasty for highrisk in-stent restenosis. Am J Cardiol 2000; 86(8A): 12 li 
  8. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Detlef G. Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. JACC 2000; 35(6): 1554-1559 
  9. Zidar J, Fry E, Lambert C. The VENUS trial: a multi-centre registry of the Cordis $Bx^{TM}$-stent platform. Am J Cardiol 2000; 86(8A): 17i 
  10. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delean JL, Garda E, Jose Calabuig J. Randomised comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions. JACC 1999; 34: 1498-1506 
  11. Chaitman BR, Rosen AD, Williams DO, Bourassa MG, Aguirre FV, Pitt B, Rautaharju PM, Rogers WJ, Sharaf B, Attubato M, Hardison RM, Srivatsa S, Kouchoukos NT, Stocke K, Sopko G, DetreK, FryeR. Myocardial infarction and cardiac mortality in the bypass angioplasty revascularization investigation (BARI) randomized trial. Circulation 1997; 96: 2162-2170 
  12. Hospital Episode Statistics. 1999/00 Key Facts and Figures. Department of Health and Human Service; 2001 
  13. 한국심장재단 . 2001년 전국 심장혈관질환 수술현황 http://www.heart.or.kr 
  14. Altman JD, Bayes-Genis A, Schwartz RS. Pathophysiology of restenosis in Restenosis: a Guideto Therapy. Ed. FaxonDP, Martin Dunitz Ltd,London; 2001 
  15. Suzuki T, Kopia GA, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointirnal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193 
  16. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 1996;98(10): 2277-2283 
  17. Gregory CR, Huang X, Pratt RE. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59(5): 655-661 
  18. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smoothmuscle cells. Circ. Res. 1995; 76: 412-417 
  19. Serruys PW, Morice MC, Sousa JE. The RAVEL study: a randomized study with the sirolimus coated Bx velocity balloonexpandable stentin the treatment of patients withde novo native coronary arterylesions. Eur Heart J 2001; 22(suppl): 2624 
  20. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, Seixas AC, Staico R, Mattos LA, Sousa AGMR, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of neointimal proliferation after implantation of sirolimus coated stents in human coronary arteries, Circulation 2001; 103: 192-195 
  21. Sousa JE, Costa MA, Abizaid A. Mid(4month) and long-terrn(1-year) QCA and three dimensional IVUS follow-up after implantation of sirolimus-coated stent in human coronary arteries. JACC 2001; 37(2): 29-32 
  22. Carter AJ, Bailey LR, Llanos G. Stent basedsirolimus delivery reduces neointirnal proliferation in a porcine coronary model of restenosis. JACC 2000; 35: 1041-1085 
  23. Klugherz BD, Llanos G, Kopia GA . Intramural kinetics of sirolimus elutedfrom an intracoronary stent. Circulation 2000; 102(18): 35-44 
  24. Lamotte M, Annemans L. A decision analytic model to evaluate the health economic value of the sirolimus-eluting stent($CYPHER^{TM}$) in acute coronary artery disease. HEDM; 2002 
  25. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, Giessen WVD,Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA, the Benestent Study Group. Randomized comparison of implantation of heparin coated stents with balloon angioplasty in selected patients with coronary artery clisease (Benestent II).Lancet 1998;352(9192): 673-681 
  26. Morice MC. A Randomized double-blind study with the Sirolimus-eluting Bx $Velocity^{TM}$ balloon expandable stent in the treatment of patients with de novo native coronary artery Lesions. ESC congress Stockholm; 2001 
  27. Kiemeneij F, Serruys PW, Macaya C, Rutsch W, Heyndrickx G, Albertsson FajadetJ, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, Disco CMC, Morel MA, Benestent I Study Group. Continued benefit of coronary stenting versus balloon angioplasty: five year follow-up of Benestent-I trial. J Am Call Cardiol 2001; 37(6): 1598-1603 
  28. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, RyanT, SmithH, Whitlow P, Wiens R, Mark DB, Rosen AD, Detre K, Frye RL, The BypassAngioplasty Revascularization Investigation (BARI) Investigators. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation(BARI) Investigators. N Eng J Med 1997; 336(2): 92-99 
  29. 건강보험심사통계연보. 건강보험심사평가원; 2000 
  30. Petitti DB. Meta-analysis, decision analysis and cost-effectiveness analysis. New York, Oxford, Oxford University Press; 1994 
  31. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi DC, Jang YS, Lam RL, Weissman NJ, Mintz GS. A Placitaxel-eluting stenting for the prevention of coronary restenosis. N Engl J Med2003; 348: 1537-1545 

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일